radiosensitivity

MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).

GSK484 hydrochloride (GTPL8577) is a reversible peptidyl-arginine deiminase 4 (PAD4) inhibitor. It binds to PAD4 with high affinity, with IC50 of 250 and 50 nM in the presence and absence of 2 mM calcium, respectively. GSK484 promotes the radiosensitivity of colorectal cancer (CRC) and inhibits NET formation in vitro and in vivo.

SKLB-163 is a small-molecule inhibitor and a RhoGDI inhibitor with oral bioactivity, cell permeability, and selectivity. This compound induces tumor cell apoptosis, inhibits proliferation and migration, and enhances radiosensitivity by downregulating RhoGDI, activating the JNK-1/caspase-3 pathway, and suppressing Akt and p44/42 MAPK phosphorylation.

1-Methylxanthine is a caffeine derivative. 1-Methylxanthine is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP). 1-Methylxanthine enhances the radiosensitivity of tumor cells.

TMU 35435 is an inhibitor of histone deacetylases (HDAC). It enhances radiosensitivity by inducing the accumulation of misfolded proteins and autophagy (autophagy) in TNBC, and inhibits the NHEJ pathway through ubiquitination of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs).

ART899 is a potent and specific conformational inhibitor of DNA polymerase θ (Polθ). It specifically inhibits the MMEJ activity of Polθ with an IC50 of 180 nM. Additionally, ART899 selectively enhances the radiosensitivity of tumor cells and possesses a strong independent antitumor effect on cancer cells.

TIP48/49-IN-1 (Compound B) is an orally active, specific RUVBL1/2 ATPase inhibitor, with an IC50 of 59 nM for purified RUVBL1/2. It disrupts the DNA replication process, causing S phase arrest, induces apoptosis, inhibits tumor growth, and enhances the radiosensitivity of non-small cell lung cancer cells (NSCLC).

Chloroxoquinoline is an anticancer agent that disrupts the DNA template of cancer cells, leading to DNA breaks and cell death. It inhibits cell invasion by downregulating the Rho/Rho kinase signaling pathway. In tumor-bearing mouse models, Chloroxoquinoline enhances the radiosensitivity of Lewis lung carcinoma cells and xenograft tumors. However, its long-term efficacy is reduced in rat models due to self-induction of CYP1A and CYP3A. Chloroxoquinoline exhibits broad-spectrum anticancer activity against non-small cell lung cancer (NSCLC), breast cancer, and gastric cancer.

5-Nitrotryptamine is a radiosensitizer with the ability to enhance radiosensitivity. It is used in research on hypoxic tumors.

SENP1-IN-3 is a distinct inhibitor of the deSUMOylation protease 1 (SENP1), designed to enhance tumor radiosensitivity.

SENP1-IN-4, a distinct inhibitor of the deSUMOylation protease 1 (SENP1), is designed to enhance tumor radiosensitivity.

SENP1-IN-1 is a distinct inhibitor of the deSUMOylation protease 1 (SENP1), designed to enhance tumor radiosensitivity.

SENP1-IN-2, a distinct inhibitor of the deSUMOylation protease 1 (SENP1), is designed to enhance tumor radiosensitivity.

E7016 (GPI 21016) is an orally available PARP inhibitor that inhibits DNA repair and enhances tumor cell radiosensitivity both in vitro and in vivo.

Sodium glycididazole (Sodium glycididazole), a radiosensitizer, enhances the radiosensitivity of nasopharyngeal carcinoma cells by increasing DNA damage and augmenting apoptosis (apoptosis) in these cells.